Skip to main content
OpenTrials
Completed

NCT Number: NCT04817449

Spectroscopy in Ovarian Cancer

Ovarian cancer is the eighth most common cause of cancer death in the world. Advanced stage at diagnosis is associated with lower survival rates, thus early detection appears to have an important role.

Raman Spectroscopy is a non-invasive technique that uses the interaction of light to identify the composition of the sample tested.

The aim of the project is to explore the use of spectroscopic techniques in the detection of ovarian cancer. There are two different assessments within the project:

1. Identify ovarian cancer in blood - Raman spectroscopic analysis will be performed on blood plasma taken from patients with suspected ovarian cancer. 2. Detect active cancer within post chemotherapy fibrotic tissue - Ex vivo Raman spectroscopic analysis of peritoneal, omental or ovarian tissues collected from patients undergoing surgical treatment for ovarian cancer.

The results of the spectroscopy will be correlated to clinical outcome and histological diagnosis respectively.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Cancer Adnexal Diseases Cysts Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Cysts Ovarian Diseases Ovarian Neoplasms Ovary Cyst Ovary Disease Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

University Hospitals Bristol and Weston NHS Trust

Bristol, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female
  • Symptoms suggestive of ovarian cancer
  • Patients undergoing treatment of Ovarian Cancer

Exclusion criteria

  • Less than 18 years of age
  • Unable to consent to the study due to communication difficulties
  • Unable to consent to the study due to lack of capacity

Treatment and study plan

Primary outcomes

  1. Ascertain the diagnostic performance of vibrational spectroscopy for detection of Ovarian Cancer

    Time frame: 2 years

    Biomarkers for ovarian cancer will be identified by analysing Raman spectral data of plasma samples taken from patient with ovarian cancer symptoms. Clinical outcome of cancer/no cancer will be used to correlate the results.

  2. Ascertain the discriminatory ability of vibrational spectroscopy to differentiate between normal, fibrotic and cancerous tissue

    Time frame: 2 years

    Samples taken from post chemotherapy patients will be analysed to identify the spectral signature of ovarian cancer in chemotherapy exposed tissue.

Secondary outcomes

  1. Performance of vibrational spectroscopy in chemotherapy response prediction

    Time frame: 2 years

    Plasma samples after 1st cycle of chemotherapy will be analysed to evaluate for changes in biomarkers after chemotherapy treatment.

  2. Performance of vibrational spectroscopy in recurrence prediction

    Time frame: 2 years

    Plasma samples after recurrence of cancer will be analysed and compared to initial spectral signature at diagnosis

Sponsors and collaborators

Lead sponsor

University of Exeter

Other

Collaborators

  • University Hospitals Bristol and Weston NHS Foundation Trust

Registry information

Official study title

Molecular Spectroscopy in Identification and Assessment of Ovarian Cancer

Important dates

Study start
2021
Primary completion
2023
Study completion
2025
First posted
Mar 26, 2021
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.